Peizhun Du1, Yongchao Liu2, Hong Ren3, Jing Zhao1, Xiaodan Zhang4, Rajan Patel5, Chenen Hu1, Jun Gan1, Guangjian Huang6. 1. Department of General Surgery, Huashan Hospital of Fudan University, Shanghai, 200040, China. 2. Department of General Surgery, Shanghai Tenth People's Hospital, Shanghai, China. 3. Department of Breast Surgery, Huashan Hospital of Fudan University, Shanghai, China. 4. Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China. 5. General Internal Medicine, Shady Grove Adventist Hospital, Rockville, MD, USA. 6. Department of General Surgery, Huashan Hospital of Fudan University, Shanghai, 200040, China. huangguangjian12@126.com.
Abstract
BACKGROUND: The prognostic significance of CC chemokine receptor type 7 (CCR7) for survival of patients with gastric cancer remains controversial. To investigate the impacts of CCR7 on clinicopathological findings and survival outcome in gastric cancer, we performed a meta-analysis. METHODS: A comprehensive search in PubMed, Embase, the Cochrane Library, and the CNKI database (1966 to November 2015) was undertaken for relevant studies. The relative risk and hazard ratios with their 95 % confidence intervals were used as measures to investigate the correlation between CCR7 expression and clinicopathological findings and overall survival rate. Sensitivity analysis was conducted to assess the stability of outcomes. RESULTS: Fifteen eligible studies comprising 1697 participants were included in our analysis. The pooled relative risks indicated CCR7 expression was significantly associated with deeper tumor invasion [0.61, 95 % confidence interval (CI) 0.45-0.84, p = 0.003], advanced stage (0.47, 95 % CI 0.32-0.69, p < 0.001), vascular invasion (2.12, 95 % CI 1.20-3.73, p = 0.009), lymph node metastasis (2.00, 95 % CI 1.48-2.70, p < 0.001), and lymphatic invasion (1.98, 95 % CI 1.43-2.72, p < 0.001) but not with age, tumor size, and histological type. The pooling of hazard ratios showed a significant relationship between positive CCR7 expression and worse 5-year overall survival rate (0.46, 95 % CI 0.31-0.70, p < 0.001). CONCLUSIONS: Our meta-analysis indicated high CCR7 expression is likely to be a negative clinicopathological prognostic factor for patients with gastric cancer and to predict a worse long-term survival outcome.
BACKGROUND: The prognostic significance of CC chemokine receptor type 7 (CCR7) for survival of patients with gastric cancer remains controversial. To investigate the impacts of CCR7 on clinicopathological findings and survival outcome in gastric cancer, we performed a meta-analysis. METHODS: A comprehensive search in PubMed, Embase, the Cochrane Library, and the CNKI database (1966 to November 2015) was undertaken for relevant studies. The relative risk and hazard ratios with their 95 % confidence intervals were used as measures to investigate the correlation between CCR7 expression and clinicopathological findings and overall survival rate. Sensitivity analysis was conducted to assess the stability of outcomes. RESULTS: Fifteen eligible studies comprising 1697 participants were included in our analysis. The pooled relative risks indicated CCR7 expression was significantly associated with deeper tumor invasion [0.61, 95 % confidence interval (CI) 0.45-0.84, p = 0.003], advanced stage (0.47, 95 % CI 0.32-0.69, p < 0.001), vascular invasion (2.12, 95 % CI 1.20-3.73, p = 0.009), lymph node metastasis (2.00, 95 % CI 1.48-2.70, p < 0.001), and lymphatic invasion (1.98, 95 % CI 1.43-2.72, p < 0.001) but not with age, tumor size, and histological type. The pooling of hazard ratios showed a significant relationship between positive CCR7 expression and worse 5-year overall survival rate (0.46, 95 % CI 0.31-0.70, p < 0.001). CONCLUSIONS: Our meta-analysis indicated high CCR7 expression is likely to be a negative clinicopathological prognostic factor for patients with gastric cancer and to predict a worse long-term survival outcome.
Entities:
Keywords:
CC chemokine receptor type 7; Meta-analysis; Prognosis; Stomach neoplasms
Authors: Michele Weber; Robert Hauschild; Jan Schwarz; Christine Moussion; Ingrid de Vries; Daniel F Legler; Sanjiv A Luther; Tobias Bollenbach; Michael Sixt Journal: Science Date: 2013-01-18 Impact factor: 47.728
Authors: Jan Sperveslage; Sunna Frank; Carola Heneweer; Jan Egberts; Bodo Schniewind; Malte Buchholz; Frank Bergmann; Nathalia Giese; Johanna Munding; Stephan A Hahn; Holger Kalthoff; Günter Klöppel; Bence Sipos Journal: Int J Cancer Date: 2012-01-11 Impact factor: 7.396
Authors: M C Dieu; B Vanbervliet; A Vicari; J M Bridon; E Oldham; S Aït-Yahia; F Brière; A Zlotnik; S Lebecque; C Caux Journal: J Exp Med Date: 1998-07-20 Impact factor: 14.307
Authors: Avan Kader; Jan O Kaufmann; Dilyana B Mangarova; Jana Moeckel; Julia Brangsch; Lisa C Adams; Jing Zhao; Carolin Reimann; Jessica Saatz; Heike Traub; Rebecca Buchholz; Uwe Karst; Bernd Hamm; Marcus R Makowski Journal: Cancers (Basel) Date: 2022-06-13 Impact factor: 6.575
Authors: Austin J Barmore; Sally M Castex; Brittany A Gouletas; Alex J Griffith; Slater W Metz; Nicolas G Muelder; Michael J Populin; David M Sackett; Abigail M Schuster; Christopher T Veldkamp Journal: Biochem Biophys Res Commun Date: 2016-06-21 Impact factor: 3.575